Category PLX

Protalix BioTherapeutics Inc

Protalix BioTherapeutics (PLX) reported fiscal 2025 results on March 18 2026

Protalix BioTherapeutics (PLX) reported fiscal 2025 results on March 18, 2026, with $51.8 million in revenues from selling goods, $52.7 million in total revenues, and a net loss of $6.6 million. The most important near-term development was not just the annual print itself, but the combination of that print with the European Commission approval of the every-four-weeks dosing regimen for Elfabrio, which triggered a $25 million milestone payment from Chiesi.

PLX Protalix BioTherapeutics Inc

The core of the Protalix model today is Elfabrio (pegunigalsidase alfa) for Fabry disease, commercialized globally by Chiesi under the two Chiesi agreements described in the FY 2024 release and 10-K. :contentReference[oaicite:2]{index=2} Protalix manufactures the drug substance in Carmiel and sells finished product to Chiesi, receiving tiered payments in the 15–35% ex-US and 15–40% US range on average selling price, linked to purchased volumes, as outlined in the “Chiesi Agreements” and “Revenues from selling goods” sections.